Vietnam Dietary Food Supplements Market

The market is estimated at USD 900 million in 2025. This represents retail revenue from vitamins, minerals, herbal and botanical supplements, protein and amino-acid products, probiotics, omega fatty acids, collagen, and other non-prescription dietary supplements. The estimate reconciles company-level sales, pack volumes, channel margins, consumer spending, and published market anchors. It excludes prescription medicines, ordinary food products, and fortified staple foods where a separately identifiable supplement revenue stream cannot be established. The 2025 estimate has a modeled confidence range of USD 810-990 million.

The market is forecast to reach USD 1,648 million by 2031, expanding at a 10.6% CAGR from 2025 to 2031. Growth is supported by larger preventive-wellness budgets, healthy-ageing needs, digital retail, pharmacy-chain expansion, premium imported formulations, and local contract manufacturing. Unit volume is expected to grow more slowly than value as consumers migrate toward probiotics, collagen, omega fatty acids, specialty women's health, sports nutrition, and clinically positioned combinations. Stronger regulation should also redirect demand from unverified products toward compliant brands.

The largest profit-pool shift will occur from basic single-nutrient products and informal retail toward specialty formulations, subscriptions, verified e-commerce, pharmacy-assisted selling, and local contract manufacturing. Online sales are modeled to increase from 34% of category revenue in 2025 to 62% in 2031. Simultaneously, average retail pack value is expected to rise from USD 17.48 to USD 21.57. Brands that combine evidence, registration, authenticity, proprietary formulations, and repeat-purchase systems can protect margin more effectively than undifferentiated sellers competing primarily on discounts.

The most material risk is a trust and compliance failure arising from counterfeit products, misleading advertising, weak scientific substantiation, or inconsistent quality. During 2025 enforcement activity, authorities reported 124 criminal cases and 944 administrative cases involving counterfeit and substandard health-related products. New contaminant limits effective August 1, 2025 increase testing and supplier-control requirements. A single product-quality event can trigger recalls, platform suspension, distributor losses, regulatory penalties, and long-term damage to a brand's customer-acquisition economics.

Vietnam ranks fourth among the selected peer markets by estimated 2025 value, behind Indonesia, Thailand, and Malaysia, but ahead of the Philippines and Singapore under the normalized scope used in this report. Vietnam's 10.6% forecast CAGR exceeds Thailand's 9.6%, Singapore's 9.5%, and the modeled Malaysian rate of 8.8%. Its competitive advantages include more than 101 million consumers, high internet adoption, domestic botanical capabilities, relatively low manufacturing costs, and growing formal pharmacy and e-commerce infrastructure.

The most important demand driver is the combination of population scale and digitally enabled preventive-health purchasing. Vietnam had 101.6 million residents in 2025, while approximately 84% of the population used the internet in 2024. This allows a new brand to educate consumers, test propositions, collect first-party data, and reach provincial demand without building a fully owned store network. However, digital availability alone is insufficient because consumers require authenticity, Vietnamese-language guidance, compliant claims, accessible pack sizes, and credible pharmacy or practitioner reinforcement.